Feedback / Questions
SC0062 - Wuxi Biocity
https://www.prnewswire.com/news-releases/biocitys-eta-selective-antagonist-sc0062-granted-breakthrough-therapy-designation-in-china-for-diabetic-kidney-disease-with-albuminuria-302491559.html
Jun 25, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next